Company
R&D·Tech
Product
Investors
Sustainability
Media
Careers
EN
Introduction
DW WAY
History
Global Network
Contact Point
R&D Overview
Research Areas
Pipeline
Open Collaboration
Biologics
Chemicals
CTD LIST
IR Highlights
Financial Info
Stock Info
IR
Sustainability Report
Compliance Program
Corporate Governance
News
Brand Resource
Company
Introduction
DW WAY
History
Global Network
Contact Point
R&D·Tech
R&D Overview
Research Areas
Pipeline
Pipeline Roadmap
Key Pipelines
Open Collaboration
Product
Biologics
Chemicals
CTD LIST
Investors
IR Highlights
Financial Info
Stock Info
IR
Sustainability
Sustainability Report
Compliance Program
Corporate Governance
Overview
Board Directors
Stockholder Info
Media
News
Brand Resource
Careers
“Korea’s first-ever SGLT2 inhibitor for diabetes treatment” Daewoong Pharmaceutical’s enavogliflozin to demonstrate remarkable blood glucose lowering effect and favorable safety in type 2 diabetic patients through phase 2 clinical trial
